Black patients are less likely than patients of other races and ethnicities to receive autologous hematopoietic cell transplants for multiple myeloma, according to a study published in the April issue of Clinical Lymphoma, Myeloma, and Leukemia.
Can AI-enabled technology safeguard hospitals, pharmacies, and medical devices from cyberattacks?
MD Anderson Cancer Center and RUSH University System for Health are collaborating to create RUSH MD Anderson Cancer Center.
Shanda H. Blackmon was named director of the Lung Institute at Baylor Medicine.
Ray Blind, Ingram Assistant Professor of Cancer Research, was named associate director for diversity, equity, and inclusion at Vanderbilt-Ingram Cancer Center.
Shutting down a gene called PRMT5 stopped metastatic estrogen receptor-positive breast cancer cells from growing after they acquired resistance to a standard therapy known as CDK4/6 inhibitors, UT Southwestern Medical Center researchers showed in a new study.
Researchers at Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital, and Houston Methodist published results of a phase I clinical trial of a novel immunotherapy for high-risk sarcomas on April 24 in Nature Cancer.
In a phase I clinical trial led by UT Southwestern Medical Center, a short interfering RNA drug directed to tumor cells effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma.
Topline results from the REMOVE certification study showed that Lindis Blood Care’s medical device Catuvab was safe and effective, meeting all primary and secondary endpoints.
Topline results from a pooled clinical study show that Mainz Biomed’s portfolio of proprietary novel gene expression (mRNA) biomarkers can be used in a next generation version of the company’s colorectal cancer screening tool. The study included new patients and subjects from Mainz Biomed’s ColoFuture (Europe) and eAArly DETECT (U.S.) clinical trials. The topline results confirm the positive efficacy results previously reported with a sensitivity for colorectal cancer of 92% with a specificity of 90% and a sensitivity for advanced adenoma of 82%, the company said.
